Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -4.17% 5.75p 5.50p 6.00p 6.00p 5.75p 6.00p 247,342 08:12:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 4.30

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
23/8/201719:29N4 Pharma - Making good drugs better.553
15/5/201712:54N4 Pharma54

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:02:395.6364,0003,602.56O
12:38:025.6375,0004,221.75O
09:23:045.688,342473.42O
07:11:515.89100,0005,885.00O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
23/8/2017
09:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 6p.
N4 Pharma has a 4 week average price of 4.75p and a 12 week average price of 4.75p.
The 1 year high share price is 12.38p while the 1 year low share price is currently 4.75p.
There are currently 74,714,285 shares in issue and the average daily traded volume is 189,889 shares. The market capitalisation of N4 Pharma is £4,296,071.39.
06/8/2017
12:50
flexton: I know I wasn't going to post again until the placing but I've just been researching reasons why the share price may have fallen at the back end of July and at the beginning of August. Did anyone take note of the news coming out about Li-ESWT and Gainswave? I'll be honest, I didn't. From the Med Pub: "Several single-arm trials have shown benefit of Li-ESWT on patient-reported erectile function scores, but data from randomized trials are conflicting, and many questions remain to be answered before we can routinely offer this treatment to patients. Thus, the search for the true clinical value of Li-ESWT for ED represents a dynamic and continuing field of enquiry". Gainswave is now being offered to treat ED. The race is on! Let's hope N4P can pull it out of the bag. Happy Sunday. Good luck for next week.
03/8/2017
16:35
flexton: Guys, I'll let you crack on. It's pointless writing on here. That said I'll come back after the placing I think is going to happen (IMHO) and see where the share price is. I'll be the first person to put my hands up and say I called it wrong. Good luck all, I hope we all make a lot of money. Ps. #Ironveld ;-)
03/8/2017
16:11
biggest bill: Flexton, only ten minutes ago you claimed that you had correctly predicted that the share price here would go under 5p. This claim was made only 2 days ago. Are you having problems remembering what you wrote?
03/8/2017
16:00
biggest bill: Flexton, your first post on N4P was on 1/8/17 and you have certainly not made a correct prediction about the share price here. Your many subsequent posts here have been ridiculous to put it mildly. For somebody who claims to hold shares here (which I don't believe for a minute), your behaviour has been bizarre.
01/8/2017
12:39
zebbo: "Inherent value here is way above the current share price". Value is way way above current share price and then some. I am going to partake in the 1000% ++ rise that is expected over the next few years. Get in early and then place in bottom draw, thats how real money is made Side note - Also not sure who wrote the last RNS as it was poorly worded and just left a load of questions unanswered and failed to highlight the commercial aspects
27/7/2017
23:11
bones: For those clearly demoralised investors who can now only see downsides (even to today's progress announcement!) due to the depressed share price should remind themselves of the array of IP and future potential that N4P possesses. Not only that but the scaremongerers saying that the company will always be seeking cash have to remember that there are warrant holders who may put in £1.8m at 8p per share over the next two years plus the company will receive plenty of grants from UK bodies like Innovate UK that helps small companies with promising developments in science. No-one is saying that, in the future, no further funds will be needed from the market but that is common for pharma cos. There are companies on Nasdaq that only earn from milestones from large pharma yet are valued in billions of dollars. Perhaps these Youtube clips might help refocus on why you are invested (and not trading) and then forget about daily movements and market swings. https://www.youtube.com/watch?v=9IvlyamyPzc https://www.youtube.com/watch?v=3DxrR6Cxd4E https://www.youtube.com/watch?v=3T14Jk2ETgk N4P is today valued in total at less than £5m. Crazy huh?
03/7/2017
18:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
17/6/2017
17:04
bones: Zebbo, I note that Pfizer article was published over two months ago so doesn't seem to have harmed N4P price since then.You say N4P could be in the right place at the right time but do you not think Pfizer could be a giant to be fighting here?I know that N4P are aware that, in any generic post-patent space, competition will be plentiful but that there should be room for everyone who has a decent improvement. Question for me is would Pfizer look to the likes of N4P to licence from or would it use its clout to do everything itself and squeeze smaller competitors?I do not have the answers, by the way :)
30/5/2017
12:40
darkinbad: Ch1rp, a double top is a technical indicator. The share price has established resistance at 9.625 so if the share price approaches it and fails to push through, pulling back with a lower end of day price, it then effectively establishes two consecutive high points at the resistance level - 'a double top'. If one does form, the share price may pull back further, possibly going to the recently established support at 8.25.
18/5/2017
12:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170823 19:29:14